Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma

Inclusion Criteria: * Life expectancy more than three months * diagnosed with multiple myeloma (MM) * relapsed following a response to any conventional MM therapy, and refractory to their most recent MM therapy * Karnofsky performance status = 60 * no electrocardiographic evidence of acute ischemia or new conduction system abnormalities * no history of myocardial infarction within last 6 months * serum concentrations of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 3X upper limit of normal (ULN) * total serum bilirubin = 2X ULN * Calculated or measured creatinine clearance \>30 mL/min * platelet count = 30 x 10(9)/L * hemoglobin concentration = 8 g/dL * white blood cell count = 2.0 x 10(9)/L Exclusion Criteria: * Patients with non-secretory myeloma, plasma cell leukemia, or POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes) * major surgery within four weeks of enrollment * severe elevated serum calcium * heart failure * receipt of chemotherapy within 21 days before enrollment, receiving immunotherapy, radiation therapy, or other investigational agents * receipt of corticosteroids equivalent to more than 10 mg/day of prednisone within two weeks before enrollment * known allergies to agents used in bortezomib (e.g., boron or mannitol) * poorly controlled hypertension, diabetes mellitus, or other serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol